Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 5
1989 2
1990 2
1991 3
1992 2
1993 2
1994 2
1996 1
1999 1
2001 4
2002 2
2003 2
2004 1
2005 5
2006 2
2007 1
2008 1
2009 3
2010 2
2013 1
2014 1
2015 2
2016 2
2018 1
2019 2
2020 7
2021 18
2022 5
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Results by year
Filters applied: . Clear all
Page 1
Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
Breining P, Frølund AL, Højen JF, Gunst JD, Staerke NB, Saedder E, Cases-Thomas M, Little P, Nielsen LP, Søgaard OS, Kjolby M. Breining P, et al. Basic Clin Pharmacol Toxicol. 2021 Feb;128(2):204-212. doi: 10.1111/bcpt.13533. Epub 2020 Nov 22. Basic Clin Pharmacol Toxicol. 2021. PMID: 33176395 Free article. Review.
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Arora P, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, Raich L, Olsson S, Danov O, Jonigk D, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S. Hoffmann M, et al. EBioMedicine. 2021 Mar;65:103255. doi: 10.1016/j.ebiom.2021.103255. Epub 2021 Mar 4. EBioMedicine. 2021. PMID: 33676899 Free PMC article.
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Gunst JD, Staerke NB, Pahus MH, Kristensen LH, Bodilsen J, Lohse N, Dalgaard LS, Brønnum D, Fröbert O, Hønge B, Johansen IS, Monrad I, Erikstrup C, Rosendal R, Vilstrup E, Mariager T, Bove DG, Offersen R, Shakar S, Cajander S, Jørgensen NP, Sritharan SS, Breining P, Jespersen S, Mortensen KL, Jensen ML, Kolte L, Frattari GS, Larsen CS, Storgaard M, Nielsen LP, Tolstrup M, Sædder EA, Østergaard LJ, Ngo HTT, Jensen MH, Højen JF, Kjolby M, Søgaard OS. Gunst JD, et al. EClinicalMedicine. 2021 May;35:100849. doi: 10.1016/j.eclinm.2021.100849. Epub 2021 Apr 22. EClinicalMedicine. 2021. PMID: 33903855 Free PMC article.
Camostat mesilate therapy for COVID-19.
Uno Y. Uno Y. Intern Emerg Med. 2020 Nov;15(8):1577-1578. doi: 10.1007/s11739-020-02345-9. Epub 2020 Apr 29. Intern Emerg Med. 2020. PMID: 32347443 Free PMC article. No abstract available.
Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M, Hofmann-Winkler H, Smith JC, Krüger N, Sørensen LK, Søgaard OS, Hasselstrøm JB, Winkler M, Hempel T, Raich L, Olsson S, Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Sheltzer JM, Kjolby M, Pöhlmann S. Hoffmann M, et al. bioRxiv. 2020 Aug 5:2020.08.05.237651. doi: 10.1101/2020.08.05.237651. Preprint. bioRxiv. 2020. PMID: 32793911 Free PMC article. Updated.
Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation.
Hofmann-Winkler H, Moerer O, Alt-Epping S, Bräuer A, Büttner B, Müller M, Fricke T, Grundmann J, Harnisch LO, Heise D, Kernchen A, Pressler M, Stephani C, Tampe B, Kaul A, Gärtner S, Kramer S, Pöhlmann S, Winkler MS. Hofmann-Winkler H, et al. Crit Care Explor. 2020 Nov 16;2(11):e0284. doi: 10.1097/CCE.0000000000000284. eCollection 2020 Nov. Crit Care Explor. 2020. PMID: 33225308 Free PMC article.
79 results